NEUROCRINE BIOSCIENCES INC Treasury Stock Acquired, Average Cost Per Share
NEUROCRINE BIOSCIENCES INC (NBIX) reported Treasury Stock Acquired, Average Cost Per Share of $0.00 per share for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-10-28.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:TreasuryStockAcquiredAverageCostPerShare · last filed 2025-10-28
- NEUROCRINE BIOSCIENCES INC treasury stock acquired, average cost per share for the quarter ending 2025-09-30 was $0.00.
- NEUROCRINE BIOSCIENCES INC treasury stock acquired, average cost per share for the quarter ending 2025-06-30 was $119.36.
- NEUROCRINE BIOSCIENCES INC treasury stock acquired, average cost per share for the quarter ending 2024-09-30 was $0.00.
- NEUROCRINE BIOSCIENCES INC treasury stock acquired, average cost per share for the quarter ending 2024-06-30 was $0.00.
| Period end | Treasury Stock Acquired, Average Cost Per Share 3 month | Treasury Stock Acquired, Average Cost Per Share 6 month | Treasury Stock Acquired, Average Cost Per Share 9 month |
|---|---|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-10-28 | $127.31 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $119.36 10-Q · filed 2025-07-30 | $127.31 10-Q · filed 2025-07-30 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-10-28 | $0.00 10-Q · filed 2025-10-28 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-07-30 | $0.00 10-Q · filed 2025-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |